HRP20192032T1 - Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina - Google Patents
Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina Download PDFInfo
- Publication number
- HRP20192032T1 HRP20192032T1 HRP20192032TT HRP20192032T HRP20192032T1 HR P20192032 T1 HRP20192032 T1 HR P20192032T1 HR P20192032T T HRP20192032T T HR P20192032TT HR P20192032 T HRP20192032 T HR P20192032T HR P20192032 T1 HRP20192032 T1 HR P20192032T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- pharmaceutical composition
- disease
- pharmaceutically acceptable
- sleep
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title 1
- 102000008834 Orexin receptor Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 208000020685 sleep-wake disease Diseases 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000019116 sleep disease Diseases 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- HUKWIAXQBOHZIX-JEBQAFNWSA-N (3-fluoro-2-pyrimidin-2-ylphenyl)-[(1r,4s,5r)-5-[5-(trifluoromethyl)pyridin-2-yl]oxy-3-azabicyclo[2.2.1]heptan-3-yl]methanone Chemical compound O([C@@H]1C[C@]2(C[C@]1([H])N(C2)C(=O)C=1C(=C(F)C=CC=1)C=1N=CC=CN=1)[H])C1=CC=C(C(F)(F)F)C=N1 HUKWIAXQBOHZIX-JEBQAFNWSA-N 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 229940032147 starch Drugs 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- -1 3-fluoro-2-(pyrimidin-2-yl)phenyl Chemical group 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 239000004097 EU approved flavor enhancer Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000019264 food flavour enhancer Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (19)
1. (3-fluoro-2-(pirimidin-2-il)fenil)((1S,4R,6R)-6-((5-(trifluorometil)piridin-2-il)oksi)-2 azabiciklo[2.2.1]heptan-2-il)metanon ili njegova farmaceutski prihvatljiva sol ili solvat za upotrebu u terapiji.
2. Farmaceutski sastav koji sadrži terapeutski efikasnu količinu (3-fluoro-2-(pirimidin-2-il)fenil)((1S,4R,6R)-6-((5-(trifluorometil)piridin-2-il)oksi)-2-azabiciklo[2.2.1]heptan-2-il)metanona ili njegove farmaceutski prihvatljive soli ili solvata i bar jednu farmaceutski prihvatljivu pomoćnu tvar za upotrebu u terapiji.
3. Farmaceutski sastav koja sadrži terapeutski efikasnu količinu (3-fluoro-2-(pirimidin-2-il)fenil)((1S,4R,6R)-6-((5-(trifluorometil)piridin-2-il)oksi)-2-azabiciklo[2.2.1]heptan-2-il)metanona ili njegove farmaceutski prihvatljive soli ili solvata i bar jednu farmaceutski prihvatljivu pomoćnu tvar, za upotrebu u liječenju bolesti, poremećaja ili medicinskog stanja, gdje je bolest, poremećaj ili medicinsko stanje poremećaj spavanja, metabolički poremećaj, neurološki poremećaj, aritmije, akutni zastoj srca, čirevi, sindrom iritabilnog crijeva, proljev, gastroezofagealna refluksna bolest, poremećaj raspoloženja, posttraumatski stresni poremećaj , panični poremećaj, poremećaj nedostatka pozornosti, kognitivni nedostaci ili zloupotreba opojnih sredstava..
4. Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj raspoloženja, posttraumatski stresni poremećaj, panični poremećaj , poremećaj nedostatka pozornosti, kognitivni nedostaci, ili zloupotreba opojnih sredstava.
5. Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj spavanja.
6. Farmaceutski sastav za upotrebu prema zahtjevu 5, gdje je poremećaj spavanja poremećaj prelaska iz stanja sna u stanje budnosti, nesanica, sindrom nemirnih nogu, „jet-lag“, poremećeno spavanje, i sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
7. Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje metabolički poremećaj .
8. Farmaceutski sastav za upotrebu prema zahtjevu 7, gdje je metabolički poremećaj prekomjerna težina, pretilost, inzulinska rezistencija, dijabetes tipa II, hiperlipidemija, žučni kamenci, angina, hipertenzija, dispneja, tahikardija, neplodnost, apneja u snu, bol u leđima i zglobovima, proširene vene ili osteoartritis.
9. Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje, neurološki poremećaj.
10. Farmaceutski sastav za upotrebu prema zahtjevu 9, gdje je neurološki poremećaj Parkinsonova bolest, Alzheimerova bolest, Touretteov sindrom, katatonija, anksioznost, delirij ili demencija.
11. Farmaceutski sastav koji sadrži terapeutski efikasnu količinu (3-fluoro-2-(pirimidin-2-il)fenil)((1S,4R,6R)-6-((5-(trifluorometil)piridin-2-il)oksi)-2-azabiciklo[2.2.1]heptan-2-il)metanona ili njegove farmaceutski prihvatljive soli ili solvata i bar jednu farmaceutski prihvatljivu pomoćnu tvar za oralno davanje.
12. Farmaceutski sastav prema zahtjevu 11 u obliku tablete, kapsule, otopine, emulzije ili suspenzije.
13. Farmaceutski sastav prema zahtjevu 11 u obliku tablete.
14. Farmaceutski sastav prema zahtjevu 13, gdje su pomoćne tvari izabrane između inertnih razblaživača, sredstava za dezintegraciju, vezivnih sredstava, maziva, zaslađivača, pojačivača okusa , bojila i konzervansa.
15. Farmaceutski sastav prema zahtjevu 14, gdje su inertna sredstva za punjenje izabrana između natrijevog i kalcijevog karbonata, natrijevog i kalcijevog fosfata, laktoze, škroba, šećera, glukoze, metil celuloze, magnezijevog stearata, manitola i sorbitola .
16. Farmaceutski sastav prema zahtjevu 14, gdje su sredstva za raspadanje izabrana između škroba, polivinilpirolidona (PVP), natrijev škrob glikolata, mikrokristalične celuloze i alginske kiseline.
17. Farmaceutski sastav prema zahtjevu 14, gdje su vezivna sredstva izabrana između škroba i želatine.
18. Farmaceutski sastav prema zahtjevu 14, gdje su maziva sredstva izabrana između magnezijevog stearata, stearinske kiseline i talka.
19. Farmaceutski sastav prema zahtjevu 11 u obliku kapsule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780378P | 2013-03-13 | 2013-03-13 | |
EP17206491.7A EP3363438B1 (en) | 2013-03-13 | 2014-03-12 | Substituted 2-azabicycles and their use as orexin receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192032T1 true HRP20192032T1 (hr) | 2020-02-07 |
Family
ID=50487148
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230633TT HRP20230633T1 (hr) | 2013-03-13 | 2014-03-12 | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina |
HRP20180303TT HRP20180303T1 (hr) | 2013-03-13 | 2018-02-20 | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina |
HRP20192032TT HRP20192032T1 (hr) | 2013-03-13 | 2019-11-08 | Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230633TT HRP20230633T1 (hr) | 2013-03-13 | 2014-03-12 | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina |
HRP20180303TT HRP20180303T1 (hr) | 2013-03-13 | 2018-02-20 | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina |
Country Status (38)
Country | Link |
---|---|
US (5) | US9611277B2 (hr) |
EP (4) | EP3363438B1 (hr) |
JP (1) | JP6275815B2 (hr) |
KR (1) | KR102209424B1 (hr) |
CN (3) | CN110669052B (hr) |
AR (1) | AR095423A1 (hr) |
AU (2) | AU2014248680B2 (hr) |
BR (1) | BR112015022294B1 (hr) |
CA (1) | CA2904618C (hr) |
CL (1) | CL2015002609A1 (hr) |
CR (2) | CR20210523A (hr) |
CY (3) | CY1120024T1 (hr) |
DK (2) | DK2970314T3 (hr) |
EA (1) | EA029276B1 (hr) |
ES (3) | ES2950032T3 (hr) |
HK (1) | HK1219725A1 (hr) |
HR (3) | HRP20230633T1 (hr) |
HU (3) | HUE036193T2 (hr) |
IL (2) | IL240466B (hr) |
JO (1) | JOP20140092B1 (hr) |
LT (2) | LT2970314T (hr) |
ME (2) | ME03572B (hr) |
MX (2) | MX368466B (hr) |
MY (1) | MY183725A (hr) |
NI (1) | NI201500130A (hr) |
NO (1) | NO3107630T3 (hr) |
PE (1) | PE20151599A1 (hr) |
PH (1) | PH12015501929A1 (hr) |
PL (3) | PL3622956T3 (hr) |
PT (2) | PT3363438T (hr) |
RS (3) | RS59466B1 (hr) |
SG (1) | SG11201507415QA (hr) |
SI (2) | SI3363438T1 (hr) |
TW (1) | TWI621618B (hr) |
UA (1) | UA118669C2 (hr) |
UY (1) | UY35409A (hr) |
WO (1) | WO2014165070A1 (hr) |
ZA (1) | ZA201507562B (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120105449A (ko) | 2009-10-23 | 2012-09-25 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤 |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
JP6262885B2 (ja) | 2014-03-06 | 2018-01-17 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | オレキシン受容体拮抗剤としてのピペリジン誘導体 |
KR102455043B1 (ko) * | 2014-09-11 | 2022-10-13 | 얀센 파마슈티카 엔.브이. | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 |
WO2016100157A2 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
EP3336088B1 (en) * | 2015-08-14 | 2021-04-21 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017088759A1 (en) | 2015-11-23 | 2017-06-01 | Sunshine Lake Pharma Co., Ltd. | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
CA2960253A1 (en) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
SG11201810600WA (en) | 2016-06-13 | 2018-12-28 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
WO2018098361A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof |
JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ, インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
AU2018326734B2 (en) * | 2017-09-01 | 2023-08-17 | Chronos Therapeutics Limited | Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists |
GB2558975B (en) * | 2017-09-01 | 2019-01-23 | Chronos Therapeutics Ltd | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
WO2020123925A1 (en) * | 2018-12-14 | 2020-06-18 | Dana-Farber Cancer Institute, Inc. | Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof |
CN113302190A (zh) | 2019-01-15 | 2021-08-24 | 吉利德科学公司 | Fxr(nr1h4)调节化合物 |
JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | Fxrアゴニストの固体形態 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674793A (en) | 1967-03-29 | 1972-07-04 | Sterling Drug Inc | 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones |
US6505492B2 (en) | 2001-04-11 | 2003-01-14 | Bethlehem Steel Corporation | Method and apparatus for forming deep-drawn articles |
EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
AU2003202753A1 (en) | 2003-02-07 | 2004-08-30 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
MXPA05008108A (es) | 2003-02-21 | 2005-09-21 | Pharmacia & Upjohn Co Llc | Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos. |
US20090005363A1 (en) | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
KR20090061041A (ko) | 2006-09-11 | 2009-06-15 | 노파르티스 아게 | 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체 |
WO2008065626A2 (en) | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
US8030495B2 (en) * | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
AR067569A1 (es) | 2007-07-17 | 2009-10-14 | Bristol Myers Squibb Co | Procedimiento para la modulacion del receptor acoplado a la proteina g gpr 119 y compuestos seleccionados |
WO2009080533A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
WO2009104155A1 (en) * | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[2.2.1]heptane derivatives |
WO2009133522A1 (en) | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
CA2730593A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
US8357700B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
US8710076B2 (en) | 2008-10-21 | 2014-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
AU2009324239A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
JP2012524760A (ja) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | オレキシンアンタゴニストとして使用される3−アザビシクロ[4.1.0]ヘプタン |
KR20120105449A (ko) | 2009-10-23 | 2012-09-25 | 얀센 파마슈티카 엔.브이. | 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤 |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
CA2778684A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
JP2013513664A (ja) | 2009-12-14 | 2013-04-22 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 架橋二環式rhoキナーゼ阻害化合物、組成および使用 |
US8697691B2 (en) | 2009-12-21 | 2014-04-15 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
US20130096141A1 (en) | 2010-06-18 | 2013-04-18 | Bernard R. Neustadt | Bicyclic heterocycle derivatives and methods of use thereof |
WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
WO2014066196A1 (en) | 2012-10-23 | 2014-05-01 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists |
KR20150082613A (ko) | 2012-11-16 | 2015-07-15 | 머크 샤프 앤드 돔 코포레이션 | 인간 포스파티딜이노시톨 3-키나제 델타의 퓨린 억제제 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
AU2015214366B2 (en) | 2014-02-06 | 2019-04-18 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
KR102455043B1 (ko) | 2014-09-11 | 2022-10-13 | 얀센 파마슈티카 엔.브이. | 치환된 2-아자바이사이클 및 오렉신 수용체 조절제로서의 이의 용도 |
-
2014
- 2014-03-11 TW TW103108293A patent/TWI621618B/zh active
- 2014-03-12 CR CR20210523A patent/CR20210523A/es unknown
- 2014-03-12 PT PT172064917T patent/PT3363438T/pt unknown
- 2014-03-12 PL PL19193122.9T patent/PL3622956T3/pl unknown
- 2014-03-12 US US14/774,555 patent/US9611277B2/en active Active
- 2014-03-12 BR BR112015022294-3A patent/BR112015022294B1/pt active IP Right Grant
- 2014-03-12 ES ES19193122T patent/ES2950032T3/es active Active
- 2014-03-12 PL PL14717576T patent/PL2970314T3/pl unknown
- 2014-03-12 RS RSP20191419 patent/RS59466B1/sr unknown
- 2014-03-12 PE PE2015001954A patent/PE20151599A1/es active IP Right Grant
- 2014-03-12 PT PT147175764T patent/PT2970314T/pt unknown
- 2014-03-12 PL PL17206491T patent/PL3363438T3/pl unknown
- 2014-03-12 LT LTEP14717576.4T patent/LT2970314T/lt unknown
- 2014-03-12 JP JP2016501487A patent/JP6275815B2/ja active Active
- 2014-03-12 MX MX2018015165A patent/MX368466B/es unknown
- 2014-03-12 RS RS20230703A patent/RS64551B9/sr unknown
- 2014-03-12 MY MYPI2015703021A patent/MY183725A/en unknown
- 2014-03-12 ES ES17206491T patent/ES2760564T3/es active Active
- 2014-03-12 ME MEP-2019-314A patent/ME03572B/me unknown
- 2014-03-12 CN CN201910948604.1A patent/CN110669052B/zh active Active
- 2014-03-12 HU HUE14717576A patent/HUE036193T2/hu unknown
- 2014-03-12 WO PCT/US2014/024293 patent/WO2014165070A1/en active Application Filing
- 2014-03-12 UA UAA201509932A patent/UA118669C2/uk unknown
- 2014-03-12 MX MX2015011815A patent/MX361529B/es active IP Right Grant
- 2014-03-12 SI SI201431351T patent/SI3363438T1/sl unknown
- 2014-03-12 CN CN201810842686.7A patent/CN108864093A/zh active Pending
- 2014-03-12 US US14/206,722 patent/US8969352B2/en active Active
- 2014-03-12 JO JOP/2014/0092A patent/JOP20140092B1/ar active
- 2014-03-12 AU AU2014248680A patent/AU2014248680B2/en active Active
- 2014-03-12 EP EP17206491.7A patent/EP3363438B1/en active Active
- 2014-03-12 EP EP23176328.5A patent/EP4272824A3/en active Pending
- 2014-03-12 DK DK14717576.4T patent/DK2970314T3/en active
- 2014-03-12 SI SI201430542T patent/SI2970314T1/en unknown
- 2014-03-12 HU HUE17206491A patent/HUE047592T2/hu unknown
- 2014-03-12 DK DK17206491T patent/DK3363438T3/da active
- 2014-03-12 CA CA2904618A patent/CA2904618C/en active Active
- 2014-03-12 RS RS20180158A patent/RS56875B1/sr unknown
- 2014-03-12 ES ES14717576.4T patent/ES2659397T3/es active Active
- 2014-03-12 CN CN201480027437.2A patent/CN105308048B/zh active Active
- 2014-03-12 LT LT17206491T patent/LT3363438T/lt unknown
- 2014-03-12 HU HUE19193122A patent/HUE063608T2/hu unknown
- 2014-03-12 KR KR1020157028720A patent/KR102209424B1/ko active IP Right Grant
- 2014-03-12 EA EA201591703A patent/EA029276B1/ru unknown
- 2014-03-12 EP EP14717576.4A patent/EP2970314B1/en active Active
- 2014-03-12 HR HRP20230633TT patent/HRP20230633T1/hr unknown
- 2014-03-12 SG SG11201507415QA patent/SG11201507415QA/en unknown
- 2014-03-12 ME MEP-2018-46A patent/ME03011B/me unknown
- 2014-03-12 EP EP19193122.9A patent/EP3622956B9/en active Active
- 2014-03-13 UY UY0001035409A patent/UY35409A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100967A patent/AR095423A1/es active IP Right Grant
- 2014-11-19 NO NO14808529A patent/NO3107630T3/no unknown
-
2015
- 2015-01-26 US US14/605,387 patent/US9447117B2/en active Active
- 2015-08-10 IL IL240466A patent/IL240466B/en active IP Right Grant
- 2015-08-24 CR CR20150433A patent/CR20150433A/es unknown
- 2015-09-02 PH PH12015501929A patent/PH12015501929A1/en unknown
- 2015-09-10 NI NI201500130A patent/NI201500130A/es unknown
- 2015-09-11 CL CL2015002609A patent/CL2015002609A1/es unknown
- 2015-10-12 ZA ZA2015/07562A patent/ZA201507562B/en unknown
-
2016
- 2016-06-30 HK HK16107630.3A patent/HK1219725A1/zh unknown
- 2016-08-26 US US15/248,945 patent/US9845333B2/en active Active
-
2017
- 2017-04-04 US US15/478,888 patent/US10183953B2/en active Active
-
2018
- 2018-02-20 HR HRP20180303TT patent/HRP20180303T1/hr unknown
- 2018-03-09 CY CY20181100284T patent/CY1120024T1/el unknown
- 2018-07-03 AU AU2018204835A patent/AU2018204835B2/en active Active
-
2019
- 2019-02-03 IL IL264606A patent/IL264606A/en unknown
- 2019-11-08 HR HRP20192032TT patent/HRP20192032T1/hr unknown
- 2019-12-02 CY CY20191101261T patent/CY1122392T1/el unknown
-
2023
- 2023-07-25 CY CY20231100361T patent/CY1126106T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192032T1 (hr) | Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina | |
JP5792061B2 (ja) | 神経及び精神障害の治療法 | |
Vecchierini | Sleep disturbances in Alzheimer’s disease and other dementias | |
Haack et al. | Simvastatin treatment attenuates increased respiratory variability and apnea/hypopnea index in rats with chronic heart failure | |
Roux et al. | Medication effects on sleep | |
EP1901747A2 (en) | Pyrimidine-based cdk inhibitors for treating pain | |
JP2017513842A (ja) | シクロプロパンアミン化合物およびその用途 | |
JP2011500697A5 (hr) | ||
JP2015521642A5 (hr) | ||
CN101955440B (zh) | 一种阿戈美拉汀新晶型及其制备方法 | |
NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
US20100204205A1 (en) | Tolerability of mirtazapine and a second active agent by using them in combination | |
WO2017086430A1 (ja) | Nashの治療又は予防のための医薬組成物 | |
RU2015142255A (ru) | Фармацевтическое комбинированное лекарственное средство | |
RU2011127382A (ru) | Замещенные тетрагидропиранспиропирролидинон и тетрагидропиранспиропиперидинон, способ их получения и применение в лечебных целях | |
HRP20171981T1 (hr) | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti | |
JP2011503233A5 (hr) | ||
Huang et al. | Effects of obstructive sleep apnea during rapid eye movement sleep on cardiac autonomic dysfunction: Results from the Shanghai sleep health study cohort | |
JP5600253B2 (ja) | 情動障害の治療のための[2−(6−フルオロ−1h−インドール−3−イルスルファニル)ベンジル]メチルアミン | |
SI3149002T1 (en) | 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators | |
WO2009023820A1 (en) | Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination | |
Amano et al. | Behavioral and psychological symptoms of dementia and medical treatment. | |
HRP20210312T1 (hr) | Tetrahidrat h3 liganda, postupak za njegovo pripremanje i farmaceutski pripravci koji ga sadrže | |
Pavese | Imaging the aetiology of sleep disorders in dementia and Parkinson’s disease | |
Cornell et al. | Moving beyond gender stereotypes |